Sandoz announces EGALITY trial results for biosimilar etanercept
Sandoz has announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.
Click on this link for more information.
